<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    7794044
   </pmid>
   <datecreated>
    <year>
     1995
    </year>
    <month>
     07
    </month>
    <day>
     27
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1995
    </year>
    <month>
     07
    </month>
    <day>
     27
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-4967
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       54
      </volume>
      <issue>
       5
      </issue>
      <pubdate>
       <year>
        1995
       </year>
       <month>
        May
       </month>
      </pubdate>
     </journalissue>
     <title>
      Annals of the rheumatic diseases
     </title>
     <isoabbreviation>
      Ann. Rheum. Dis.
     </isoabbreviation>
    </journal>
    <articletitle>
     Intra-articular triamcinolone hexacetonide in knee osteoarthritis: factors influencing the clinical response.
    </articletitle>
    <pagination>
     <medlinepgn>
      379-81
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To assess the efficacy of a single intra-articular injection of triamcinolone hexacetonide (THA) in knee osteoarthritis (OA) and examine factors which may relate to treatment efficacy.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      Eighty four patients with clinical and radiographic evidence of knee OA were recruited and randomly allocated to receive either THA (20 mg in 1 ml) or placebo (0.9% normal saline, 1 ml). Follow up assessments evaluated the following outcome variables: patient opinion of overall change in the treated knee, visual analogue pain score (VAS), distance walked in one minute (WD), and Health Assessment Questionnaire modified for lower limb function (HAQ).
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Seventy eight percent of THA and 49% of placebo treated patients reported overall improvement at week 1 (p &lt; 0.05). At week 6, improvement was reported in 57% and 55% of patient groups, respectively. VAS improved in both groups at week 1 (THA, p &lt; 0.001; placebo, p &lt; 0.05) and week 6 (both p &lt; 0.01). Improvement in VAS was significantly greater among THA treated patients at week 1 only (p &lt; 0.01). Subgroup analysis of THA treated patients revealed greater improvement in VAS among patients with clinical evidence of an effusion (p &lt; 0.05), and those who had synovial fluid successfully aspirated at the time of injection (p &lt; 0.01). WD improved in THA treated patients at week 1 (p &lt; 0.001), and in both groups at week 6 (THA, p &lt; 0.001; placebo, p &lt; 0.01). Improvements in HAQ were seen in THA patients only at weeks 1 and 6 (p &lt; 0.05). Regression analysis did not identify any additional clinical, radiographic, or synovial fluid characteristics which influenced the response.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      THA provided short term pain relief in knee OA. Increased benefit was associated with both clinical evidence of joint effusion and successful aspiration of synovial fluid at the time of injection.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Rheumatology, Royal London Hospital, Whitechapel, United Kingdom.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Gaffney
      </lastname>
      <forename>
       K
      </forename>
      <initials>
       K
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Ledingham
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Perry
      </lastname>
      <forename>
       J D
      </forename>
      <initials>
       JD
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Ann Rheum Dis
    </medlineta>
    <nlmuniqueid>
     0372355
    </nlmuniqueid>
    <issnlinking>
     0003-4967
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Inflammatory Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      5611-51-8
     </registrynumber>
     <nameofsubstance>
      triamcinolone hexacetonide
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      76-25-5
     </registrynumber>
     <nameofsubstance>
      Triamcinolone Acetonide
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1993 Nov 20;307(6915):1329-30
     </refsource>
     <pmid version="1">
      8257889
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Rheum. 1994 Mar;37(3):414-23
     </refsource>
     <pmid version="1">
      8129797
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Rheum Dis. 1993 Apr;52(4):258-62
     </refsource>
     <pmid version="1">
      8484690
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Rheum Dis. 1991 Jul;50(7):467-70
     </refsource>
     <pmid version="1">
      1877852
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Rheumatol. 1991 Apr;18(4):591-8
     </refsource>
     <pmid version="1">
      2066950
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br J Rheumatol. 1991 Jun;30(3):199
     </refsource>
     <pmid version="1">
      2049581
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Rheum. 1985 Nov;28(11):1267-74
     </refsource>
     <pmid version="1">
      4063001
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Clin Rheum Dis. 1985 Aug;11(2):175-85
     </refsource>
     <pmid version="1">
      2931235
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Rheum Dis. 1989 Apr;48(4):271-80
     </refsource>
     <pmid version="1">
      2712610
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Rheum. 1989 Feb;32(2):181-93
     </refsource>
     <pmid version="1">
      2920053
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Rheum. 1987 Aug;30(8):914-8
     </refsource>
     <pmid version="1">
      3632732
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Rheumatol Rehabil. 1980 Nov;19(4):212-7
     </refsource>
     <pmid version="1">
      7010511
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Rheumatol. 1980 Nov-Dec;7(6):850-6
     </refsource>
     <pmid version="1">
      7009857
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arthritis Rheum. 1970 May-Jun;13(3):236-43
     </refsource>
     <pmid version="1">
      5423815
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Rheum Dis. 1993 Jul;52(7):520-6
     </refsource>
     <pmid version="1">
      8346979
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Topical
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Inflammatory Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Injections, Intra-Articular
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Knee Joint
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Osteoarthritis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Regression Analysis
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triamcinolone Acetonide
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      analogs &amp; derivatives
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC1005598
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1995
     </year>
     <month>
      5
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1995
     </year>
     <month>
      5
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1995
     </year>
     <month>
      5
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     7794044
    </articleid>
    <articleid idtype="pmc">
     PMC1005598
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

